Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
significant pain in the arm where the vaccine was administered; limit mobility, making it difficult to lift the arm; This spontaneous report was received from a consumer of unknown age and gender referring to him/herself. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 05-FEB-2025, the patient was vaccinated with a dose of Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) solution for injection (dose number, dose, strength, batch/lot #, expiration date, route and anatomical site were unknown) for prophylaxis. On 06-FEB-2025 (also reported as on the day following vaccination), the patient experienced significant pain in the arm where the vaccine was administered (severe) (vaccination site pain). The pain was severe enough to limit mobility, making it difficult to lift the arm (injected limb mobility decreased). At the reporting time, the outcome of the events was unknown. The causal relationship between the events and Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) was unknown.